1. INTRODUCTION
âș Leishmaniasis are a group of infections caused by
intracellular protozoan parasites belonging to the
genus Leishmania, family Trypanosomatidae, order
Kinetoplastida.
âș Different names : Oriental sore, Aleppo evil,
Delhi boil, Baghdad sore, Rose of Jericho, Uta,
Espundia (mucocutaneous), kala-azar, Black
fever (visceral)
2. CLASSIFICATION
âș Depending on the extent and severity of involvement,
infections in the human host can be classified as
âą - Cutaneous leishmaniasis
âȘ New world â L.braziliensis, L.mexicana
âȘ Old world â L.major, L.tropica, L.aethiopica, L.infantum
âą - Diffuse cutaneous leishmaniasis â L.mexicana,
L.aethiopica
âą - Mucocutaneous leishmaniasis â L.braziliensis,
L.aethiopica
âą - Visceral leishmaniasis â L.donovani, L.infantum
âș Based on the location of enzymatically active proteins
(isoenzymes), leishmaniasis has been reclassified into
ZYMODEMES. Zymodemes are defined as group of
leishmania organisms that share same electrophoretic
migration pattern of isoenzyme
3. EPIDEMOLOGY
âș VL:- Prevelant in all continents
except Australia & Antarctica.
âș Affects 88 countries worldwide &
350 million people live in these
endangered zones
âș Highest in central & South
America, Southern Europe, Central
Africa & parts of Southern &
central Asia.
âș CL - 1.5-2 million new cases each
year
âș 90% are in Afghanistan, Algeria,
Iran, Iraq, Saudi Arabia, Syria,
Brazil and Peru.
4. EPIDEMOLOGY
In India :
âș VL- 90% cases in Bihar, followed by West Bengal & Eastern
UP.
âș CL â PKDL- North Eastern India
âș L. Tropica â Delhi, HP, Punjab, Haryana, Rajasthan
5. TRANSMISSION
âș Bite of an infected Sand fly
âș Rarely â 1. Tranfusion
2. Sexual intercourse
3. Placental transfer
4. Lab accident
PARASITE
âș Obligate intracellular parasite
âș Completes life cycle in two hosts and exists in three
morphologic types:
Amastogote â Non flagellate form, in macrophage / RE cells of
vertebrates.
Promastigote â flagellate form, in intestines of invertebrates
Paramastigote â Transitional stage between two invertebrates.
6. VECTOR : Sandflies
âș Phlebotomine sandfiles of genus:
- Phlebotomus â Old world
- Lutzomyia and Psychopyguâ New World
âș Only females are hematophagus (blood sucking)
âș More common in warm months.
âș Pass through ordinary mesh screens and mosquito nets.
âș Limited flight range â 250 mt.
RESERVOIR
âș Rodents â Visceral
âș Dogs â Cutaneous
âș Others -rats , mice, cats, gerbits.
In India, man is the most common reservoir for cutaneous
leishmaniasis.
7. LIFE CYCLE OF LEISHMANIA
Amastigate form (Inf. Mammalian
tissue or blood)
Midgut of female
sandfly
Promastigate
multiplication
Migrate to
pharynx &
proboscis
Injected into new
mammalian host Enter dermis
Phagocytosed by
macrophages
Amastigate form
Multiplication
Disrupt macrophages
Release amastigotes
Enter new
macrophages
8. IMMUNOPATHOGENESIS
âș Susceptibility to disease depends on the T-cell &
macrophage response
âș Expansion of the Th1 subset with production of IL-2 & IFN-Îł
leads to resolution of infection, while Th2 proliferation & IL-4
production leads to progression of the disease
âș Factors that determine the type of response include
âą Antigen presenting cells
âą Antigenic load
âą Type & amount of cytokines present at the time of
inoculation of parasites
âą Specific leishmanial antigen
9. ADHESION & ESCAPE MECHANISMS OF
LEISHMANIA spp.
âąBinds lectin like binding sites on CD8+ cells
& mediates adhesion to macrophages
âąInhibits insertion of C5b9 complex in
membrane, preventing lysis
âąInhibits generation of respiratory bursts
through inhibition of protein kinase C
âąInhibition of lysosomal ÎČ galactosidase
âąOxygen radical scavenger
âșLipophosphogly
can
Mechanism of interaction with
host
Leishmania
10. ADHESION & ESCAPE MECHANISMS OF
LEISHMANIA spp.
âąProtease capable of degrading lysosomal
enzymes
âąDegradation of hydrogen peroxide
âąInhibition of oxidative burst
âșGlycoprotein 63
âșSuperoxide
dismutase
âșAcid
phosphatase
Mechanism of interaction with
host
Leishmania
11. CLINICAL FEATURES
âș Infection with Leishmania can either lead to clinically silent
disease or a spectrum of clinical signs depending on
âą Immunological status of the individual
âą Genetic background
âą Nutritional status of the host
âą Number of parasites and their virulence factors
âą Site of inoculation
âą Composition of sandfly saliva
12. Mucocutaneous form
âąSkin lesions- papules, ulcers &
nodules
âąMucosal lesions present with
in 2 years of skin lesions in
50% of cases
âą most common site is nose
where it starts as a nodule on
the inferior turbinate or
septum f/b pharynx,palate,
larynx & upper lip l/t
destruction of cartilage &
disfigurement â ESPUNDIA
âąEarlier seen in 80% cases but
now <5%
âąLutzomya
longipalpis
âąLu. umbratilis
âąLu. spinicrassa
âąLu. trapidoi
âąLu. migonei
âąPhlebotomus
yucumensis
âąP.lianosmartinsi
âąL.braziliensis
âącomplex
âąL.braziliensis
braziliensis
âąL.braziliensis
guyanensis
âąL.braziliensis
panamensis
TYPE OF DISEASEVECTORAGENT
13. âąVisceral involvement not
usually seen but death can
occur due to secondary
bacterial infection, pharyngeal
obstruction & malnutrition
TYPE OF DISEASEVECTORAGENT
14.
15.
16. âąMucocutaneous form
âąSmall erythematous papules
occur at site of insect bite â
ulcerated nodule â heal
leaving behind a depressed
scar
âąEars are involved in 40-55% of
cases
âąCutaneous nodules are the
most common presentation in
Texas
âąMay cause Diffuse cutaneous
leishmaniasis
âąLutzomya
anthopora
âąLutzomya
diabolica
âąLutzomya
olmeca olmeca
âșL.mexicana
complex
âșL.mexicana
amazonensis
âșL.mexicana
pifanoi
âșL.mexicana
aristedesi
âșL.mexicana
garnhami
âșL.mexicana
venezuelensis
TYPE OF DISEASEVECTORAGENT
17.
18. âąTwo different forma are
recognized-
âąCutaneous Andrean form â c/a
UTA
âąAmazonian jungle form â has
mucous membrane
involvement resembling
ESPUNDIA
âąLutzomya
noguchii
âąLutzomya
verrucarum
âąLutzomya
peruensis
âșL.peruviana
TYPE OF DISEASEVECTORAGENT
19.
20. Cutaneous form
âąc/as Oriental sore ( dry),
Aleppo button, Jericho boil,
Pendinnsk ulcer, Urban or
Anthroponotic leishmaniasis
âąStarts as a small brownish
nodule after an incubation
period of about 2 months
âąIncreases in size to 1-2 cms
in diameter over 6 months
âąUlcers & sores may develop
which heal by permanent
scarring in 8-12 months
âąP.perfiliewi
âąP.pappatasi
âąP.sergenti
âąP.longicuspis
L.tropica
TYPE OF DISEASEVECTORAGENT
21.
22. Cutaneous form
âąWet form of oriental sore, also
c/as zoonotic or rural
leishmaniasis
âąStarts as a small papule which
appears immediately after
insect bite or after 2-4 weeks
âąEnlarges in size & becomes
crusted in center, which on
removal shows an ulcer
âąHeals with depressed scar after
6-12 months but may remain
active >24 months â NON
HEALING CHRONIC
CUTANEOUS LEISHMANIASIS
âąP.duboscqi
âąP.pappatasi
âąP.salehi
âąP.caucasicus
L.major
TYPE OF DISEASEVECTORAGENT
23. âąSub cutaneous nodules
develop along lymphatics
âąLymph nodes are enlarged
âąNo mucous membrane
involvement
TYPE OF DISEASEVECTORAGENT
24.
25.
26. Cutaneous form
âąSimilar to L.major
âąIn 20% cases, widespread
involvement that resembles
lepromatous leprosy
âșL.aethiopica
TYPE OF DISEASEVECTORAGENT
27.
28. âąViscerocutaneous form
âąCauses MEDITERRANEAN or
INFANTILE KALA AZAR
âą90% of affected people are
children < 5 years
âąCutaneous lesions are usually
more inflammatory & more
likely to be solitary than those
caused by L.major
âąP.anasi
âąP.longicuspis
âąP.major
âąP.orientalis
âąP.perniciosus
âąP.tobbi
âąP.martini
âąP.argentipis
âąP.chinensis
L.infantum
TYPE OF DISEASEVECTORAGENT
29. LEISHMANIASIS RECIDIVANS
âș Also c/as recurrent leishmaniasis, Metaleishmaniasis,
Leishmaniasis recidiva cutis, lupoid leishmaniasis, Late
cutaneous leishmaniasis
âș Refers to development of new lesions in the center or
periphery of a scar of healed lesion of leishmaniasis
âș First reported by Berlin in cases of oriental sore
âș Causative organism â L.tropica in middle east
L.braziliensis in South America
âș Rare in the New World, with only 11 cases reported so far
âș Recurrent disease is due to reactivation of dormant
organism, with period of dormancy ranging from 1-15 years
30. LEISHMANIASIS RECIDIVANS
âș Leishmania strain in 50% of recurrent lesions are different
from the initial strain, suggesting
âȘ Change in immune status of host
âȘ An exogenous re-infection
âș Presents clinically as scaly, erythematous papules with in
the scar of healed lesions
âș sometimes ulcers, psoriasiform lesions or veruccous lesions
may be present
âș Lesions tend to resist treatment & become chronic
31.
32. POST KALA AZAR LEISHMANIASIS
âș PKDL is a complication of VL, seen in patients who
have recovered from VL & who are otherwise well
âș Seen mainly in Sudan & India, where it follows VL in
50% & 5-10% of cases respectively
âș Causative organism is L.donovani
âș Important role in inter epidemic periods of VL,
acting as reservoir of infection
âș Pathogenesis is immunologically mediated
âą High conc. of serum IL-10 in VL patients predict
development of PKDL
âą production of IFN-Îł by PBMC after treatment of VL
coincides with appearance of PKDL lesions
33.
34. POST KALA AZAR LEISHMANIASIS
TYPE OF RASH
âș In Sudan, most common in papular or nodular rash (
51%)
âą Other presentstions include â maculopapular (23%)
micropapular- measles like
(17%)
macular (9%)
âș In India, there are 3 main presentations â
âą Erythema & induration on butterfly area of face which
shows photosensitivity
âą Multiple symmetric hypopigmented macules which
may coalesce
âą Combination of papules, nodules & plaques
35.
36. POST KALA AZAR LEISHMANIASIS
âș Uncommon presentations include â Annular, Warty,
Papillomatous, Fibroid or Xanthomatous types
âș Ulceration is not a feature of Indian or Sudanese PKDL
DISTRIBUTION
âș In Sudanese PKDL, lesions typically appear around mouth &
spread to other parts of face, then to upper arms & chest
âș Indian PKDL also shows predilection for face & less
frequently over trunk & arms
âș After treatment, lesions around mouth remain longest & are
first to recur in case of relapse
âș In severe cases, mucosal lesions may appear on lips & palate
âș Exposure to uv rays may be important in pathogenesis
âș Lesions may show koebnerization
37. POST KALA AZAR LEISHMANIASIS
CLINICAL GRADES OF SEVERITY
âș GRADE 1 â scattered maculopapular or nodular rash over
face, with or without some lesions on extremities
âș GRADE 2 â dense maculopapular or nodular rash over
face, extending to chest, back, upper arms & legs with
scattered lesions on forearms & legs
âș GRADE 3 â maculopapular or nodular rash covering most
parts of body, including hands & feet; crusting, ulceration,
scaling, sloughing and mucosal involvement can occur
38. INVESTIGATIONS
I. Demonstration of parasite
âș Direct smears â SSS- Giemsa /Wrightâs or leishmanin stain.
âș Tissue smears â from edge of lesionâs
âș Skin Bx â from edge
âș FNAC.
âș Nasal mucosal scrapings âMCL.
II. Culture
âș Promastigste form is seen
âș Various culture media include
âȘ Novy, Mcneal Nicole (NNN) media
âȘ Schneiderâs culture medium.
âȘ Rabbit blood agar.
39.
40. III. Animal Inoculation
âș When parasite load in tissues is low
âș Biopsy or aspirate specimens may be inoculated into
âą Mouse foot pad â L. tropica
L. mexicana
âą Hamsterâs foot pad â other species
IV.Leishmanin skin test (Montenegro test)
âș I/D test â Non-endemic areas â diagnostic
Endemic areas â survey work.
âș 0.1 to 0.2 ml of antigen â 5 x 106
promastigote in 1
ml of 0.5% phenolized saline. Each 0.1 ml = 1 million
organisms.
INVESTIGATIONS
41. âș Evokes delayed type of hypersensitivity response.
âș Read after 48-72 hours
âș Induration > 5mm is positive
Grade I : 5-6 mm induration
Grade II : 7-8 mm induration
Grade III : > 8 mm induration
Grade IV : Blisters
âș Negative in VL, DCL and Indian PKDL
âș Positive in 90-98% patients of CL, MCL and African PKDL
âș Cannot distinguish between active & quiescent disease
âș False +VE â Glandular tuberculosis
Lepromatous leprosy
INVESTIGATIONS
45. VI.Polymerase Chain reaction
âș PCR Assay can detect parasite DNA or RNA a few
weeks ahead of appearance of clinical signs and
symptoms.
âș PCR assay has also been used for post therapeutic
follow up and for detection of relapse among HIV
infected patients.
âș A PCR-ELISA technique developed recently is
reported to be sufficiently sensitive and specific for
diagnosis of MCL.
âș PCR was found to be 100% specific and sensitive
method
JAAD 2003
INVESTIGATIONS
46. INVESTIGATIONS
VII. Serology
âș More helpful in VL.
âș Unreliable in CL â Sensitively ~ 70%
Specificity â low
1. Indirect immunofluorescent antibody test
(IFAT) â High specificity and sensitivity
2. ELISA â High sensitivity modification of this method
â dot â ELISA is a simpler immunoassay.
3. Western blot â sensitive
4. Direct agglutination test (DAT) â specificity
similar to IFAT but low sensitivity.
47. INVESTIGATIONS
5. Indirect immunoperoxidase assay (IPA)
More sensitive and specific than IFAT
6. Immunochromatographic ( rk39) test â sensitivity &
specificity of strip test are 82.4% & 100% resp. compared
to 100% & 92.7% for IFAT test
âș For cutaneous leishmamasis â diagnosis rests on finding
parasite in the stains
âș PCR is useful for confirming the diagnosis.
âș IFAT â diagnosis in early stages.
48. TREATMENT OF CUTANEOUS
LEISHMANIASIS
âș CL heals spontaneously in 6 months â 1 yr without
treatment, so expectant approach may be appropriate
particularly in endemic area.
âș Patients requiring active treatment are :
âȘ Lesions on cosmetically or functionally important sites
such as face or hands
âȘ Associated lymphangitis
âȘ Multiple or persistant lesions
âȘ L. braziliensis/ panamensio âchange into MCL.
âȘ Lesions are large or overlie a joint.
Patients with MCL, DCL, PKDL do not heal without
treatment and require adequate systemic therapy
49. TREATMENT
Pentavalent antimony
âș Antimony was first used in treatment of leishmaniasis
in 1912 & in its current formulation since 1945
âș Only agent with clearly favourable therapeutic index
âș Both trivalent and pentavalent compounds tried â
pentavalent is less cardiotoxic.
âș Route â I/M or I/V
âȘ I/M is preferred â ease of administration
Less toxic effects.
âą Oral and rectal route â often not tolerated by
patients.
50. TREATMENT
âș Preparations
âȘ Sodium stibugluconate â pentostam (UK)
[100mg/ml] sodium antimony gluconate - India
(SAG)
âȘ Meglumine antimonate â (85 mg/ml] Glucantime.
âȘ These two drugs are equivalent in terms of
efficacy and toxicity.
âș Dose : 20 mg/kg/day
âș To minimize phlebitis â given as an I/V infusion in
150 ml of 5% dextrose over 2 hours.
51. TREATMENT
Duration of treatment
âș CL â 20 days
âș VL â 28 days
âș Early MCL â 28 days
âș PKDL â at least 4 months
Patient should be examined for clinical response 6
weeks after completing therapy and for 1 year for
overt sign of relapse
Mode of Action
1. Inhibition of synthesis of proteins, RNA and DNA â
Interfering with phosphorylation of ATP and GTP
which interferes with glycolysis and fatty acid
oxidation.
2. Anti-inflammatory effect
52. TREATMENT
ADVERSE EFFECTS
âș Well tolerated , both in children and adults
âș Common side effects include - Nausea, headache,
lethargy, myalgia, arthralgia.
âș Pain at injection site
âș Chemical pancreatitis (increase lipase/amylase)
53. TREATMENT
âș Cardio toxicity : monitered by ECG changes
âȘ Decrease T wave amplitude
âȘ T-wave inversion
âȘ Concave ST segment
âȘ QT prolongation
âș T/T should be interrupted if :
âȘ QT > 0.5 secs.
âȘ Significant arrhythmias
âȘ 5 fold elevation of LFT
âȘ Concave ST
âș Can be resumed cautiously after 1-2 days to avoid
resistance
âș Recurrent episodes of toxicity â switch to alternate drug.
54. TREATMENT
âș Transient increase in liver enzymes
âș Can be given safely in pregnancy
Monitoring
âș HMG, S. biochem., ECG, Amylase âtwice a week
Resistance
1. Primary resistance â Bihar (>30% pts. Of VL)
2. Secondary resistance â due to inadequate doses
and/or duration of treatment
55. âș Intralesional treatment
- For solitary uncomplicated CL lesions antimonials can
be injected intralesionally.
- Undiluted solution is infiltrated into the base and
edges of the ulcer or nodule so that blanching occurs.
- Injections are repeated every 2-3 days for 2-3 weeks.
TREATMENT
56. TREATMENT
Amphotericin B.
âș TOC in antimony resistant patients.
âș Polyene antibiotic from Streptomyces nodosus.
âș Route â slow i/v with 5% dextaose.
Mechanism of action :
1. Interference with permeability of cell membrane.
2. Immuno modulatory effects.
Dose
âș intital test dose â 1 mg
âș usual daily dose ; started with 250 ”g / kg/ day â
gradually increased to 1mg/kg/day infused over 2-4
hours.
57. TREATMENT
Adverse effects
âą Hypersensitivity reactions â fever, rigors, hypotension,
nausea, vomiting, tinitus, bronchospasm, anaphylactoid
reaction.
âą Phelbitis at site of injection
âą Nephrotoxicity : in almost 100% patients
âȘ Both glomerular and tubular damage
âȘ RTA
âȘ Incresed excretion of K & Mg l/t hypokalemia
& hypomagnesiumia
âȘ Nephrocalcinosis
.
âą Reversible normocytic normochromic anaemia
âą Visual disturbances
âą Ventricular arrhythmias â sudden cardiac arrest â with high
dose or rapid infusion
58. TREATMENT
LIPID â associated Amphotericin B
âș Three formulations are available
i) Liposomal (Am Bisome)
ii) Colloidal dispersion (ABCD)
iii) Lipid complex (ABLC)
âș Advantages
âą Rapidly effective
âą Taken up by macrophages and reaches high
concentration at infection site
âą Less s/e - no nephrotoxicity
- no local toxicity
âą Can be used at higher doses â 3-4 mg/kg
âș Disadvantages : More expensive
59. TREATMENT
Physical Modalities
âș Local heat : attractive, non toxic, inexpensive &
simple treatment option
âą infrared radiation used to raise the skin temperature
to 55 C for 5 min
âș L. braziliensis and L. mexicana are particularly heat
sensitive.
âș Mechanism of action
Inhibition of amastigote replication
90% cure rate with single treatment with infra-red
radiation
99% cure rate with two treatments.
60. TREATMENT
âș Cryotherapy : Useful for small lesions (<1 cm diameter)
âȘ 30-90 sec cryoapplications performed with CO2 cryosurgical
machine with 1 cm cryoprobe tip, include the skin 2 mm
outside the lesions
âȘ Complete response reported with average of 2 treatments.
âȘ A large controlled study in Saudi Arabia showed the success
rate to be <30% with NO cryomachine
âȘ Combination of cryotherapy & I/L stibugluconate superior
to either alone
âș Other physical modalities used are
âą CO2
laser
âą curretage
âą electrodessication
âą surgical excision
61. TREATMENT
TRADITIONAL ANTI-INFECTIVE AGENTS
âș Dapsone : 200 mg/day for 45 days cure rate â 82%
(Dogra et al)
âą Exact mechanism not known, thought to decrease
phospholipid synthesis and /or interfere with folic acid
synthesis.
âș Rifampin : 600-1200 mg/day (0-80% cure rate)
âș Metronidazole : 250 mg tds for 10 days,3 cycles with 10
days rest (Pederson et al)
âą 78% recovery rate with 250 mg bd for 15 days in
L.mexicana infection ( Beltran et al,1967 )
âą subsequent studies â no clinical improvement.
62. TREATMENT
âș Cotrimoxazole : 160/ 800 mg BD for 4 weeks
âą 33 of 36 pts. showed resolution in 3-14 weeks
(Kandil, 1973)
âą Efficacy similar to placebo in subsequent studies.
âą Allopurinol : 20 mg/kg/day for 28 days
âą A large placebo controlled double blinded study from
Colombia concluded that allopurinol monotherapy is
ineffective against Colombian cutaneous disease and
is unlikely to be effective against cutaneous disease
due to other organisms
âą Combined therapy with allopurinol & meglumine
antimoniate has shown better response than either of
the two drugs used alone
JAAD 2002
63. TREATMENT
Oral Azoles
âș Ketoconazole : 200-400 mg /day x 4 wks.
âȘ 70% cure rate â L. major (Weinrauch et al)
âȘ ineffective in â L. tropica and aethiopica.
âȘ 89% cure rate â L. mexicana
âș Itraconazole : 200 mg/ day x 4-8 wks
âȘ 79% cure rate â old world CL (IJD â 1994)
âȘ 66% cure rate from India (Dogra et al â IJD 1990)
64. TREATMENT
âș TOPICAL AGENTS
âș Topical paromomycin 15% in methylbenzethoniumchloride
applied twice daily for 10-30 days is effective in Israel in
L.major CL
âș In open study, topical paromomycin was found to be
equally effective as i/l meglumine antimoniate for
treatment of L.major CL
Euj J Dermatol 2005
65. âș Pentamidine
âș For cutaneous leishmaniasis the high cure rate associated with low
dose of pentamidine given for a shorter period makes it an
attractive alternative to sodium stibugluoconate and treatment of
choice in cases of Stibugluconate treatment failure.
âș Pentamidine mesylate and isethionate are safe and effective drugs
in treatment of New World CL (Esther J.S. et al )
32/38 (84)2 mg/kg q.o.d., 4Open-label
nonrandomized
23/24 (96)2 mg/kg q.o.d., 7Open-label
nonrandomized
No. of patients cured/total
no. of patents (%)
Dosage/no. of
injections
Study design
Efficacy of pentamidine regimens for the treatment of cutaneous
leishmaniasis in Colombia.
67. TREATMENT
Miltefosine
âș Phosphorylcholine ester of hexadecanol, a membrane
active alkylphospholipid
âș First effective oral agent for VL, including antimony
resistant cases.
âș Topical treatment with miltefosine has been shown to
efficiently reduce parasite load in experimental cutaneous
leishmaniasis.
âș In an open label study in Colombia, 4 weeks treatment
with 133 and 150 mg of miltefosine daily cured 100% and
89% respectively â American cutaneous leishmaneasis
(Soto J et al 2001)
68. TREATMENT
âș In a controlled study in Columbia & Guatemala, miltefosine
given in a dose of 2.5 mg/kg body weight for 28 days
produced 91% cure rate for L.panamensis infection and
50% cure rate for L. braziliensis & L. mexicana compared
to 38% & 20% for placebo respectively
âș Was well tolerated, adverse effects seen were mostly
nausea, mild elevation in creatinine levels
Trans R Soc Trop Med Hyg. 2006
69. TREATMENT
âș In a trial comparing the efficacy of miltefosine & sodium
stibugluconate in treatment of VL in an Ethopian population
with high prevelance of HIV infection, there was 88% initial
cure rate in both the groups, mortality was 2% & initial
treatment failure 8% with miltefosine compared to 8% &
1% resp with SSG
âș Among HIV+ patients, cure rate, relapse rate & mortality in
miltefosine group was 60%, 10% & 6% compared to 65%,
2% & 12% with SSG.
âș In HIV+ patients, miltefosine is a much safer, though
slightly less effective than SSG in treatment of leishmaniasis
Clin Infect Dis,2006
70. TREATMENT
Photodynamic Therapy
âș In a randomized placebo controlled trial, efficacy of
Photodynamic therapy was compared with paromomycin &
placebo
âș Group 1 was treated with weekly topical PDT, and groups 2
and 3 received twice-daily topical paromomycin and
placebo, respectively. The duration of treatment was 4
weeks for all groups. These groups were followed for 2
months after the end of treatment.
âș At the end of the study, complete improvement was seen
in 29 of 31 (93.5%), 14 of 34 (41.2%) and 4 of 30 lesions
(13.3%) in groups 1, 2 and 3, respectively (P<0.001). At
the same time point, 100%, 64.7% and 20% of the lesions
had parasitological cure in group 1, 2 and 3, respectively
(P<0.001)
71. TREATMENT
Immunotherapy
âą Interferon-Îł â Intralesional treatment has been tried for
cutaneous lesions
âą In one study in L. braziliensis infection, 12 of 13 lesions
became smaller after injection.
âą IFN-Îł was also compared with antomony.
âȘ I/L infiltration once a week x 5 weeks
âȘ 100% cure rate with antomony treated lesions Vs 38% of
IFN-Îł treated lesions â L. tropica
âą Recombinent IL-2 has been used to treat a few patients
with disseminated cutaneous leishmaniasis.
72. TREATMENT
Immunochemotherapy
In a double-blind placebo controlled study of 102 patients
with American CL, combination of a single âstrain
leishmania amazonensis killed promastiote vaccine with
half dose of amtimonial â 100% cure rate after 4 series of
treatments [10-day series at an interval of 10 days]
compared to 82% in control group.
IJD 2002
73. TREATMENT
âș Imiquimod
âą Another topical agent under investigation for cutaneous
leishmaniasis
âą Immunomodulator developed to geintal warts.
âą It produced 90% cure rate in patients who had failed to
respond to antimonials alone when it was used in
conjunction with antimonials in peru. (Arevaloi et al)
Clin Infect Dis
2001
âą 5% Imiquomod with or without I/L meglumine antimoniate
is more effective than I/L meglumine antimoniate alone in
treatment of old world CL
JAAD 2005
74. LEISHMANIASIS IN HIV INFECTION
âș VL is the fourth most common opportunistic parasitic
disease in HIV-positive individuals
âș VL promotes the development of AIDS-defining
conditions and HIV infection increases the
development of VL by 100-1000 times in endemic
areas, reduces the therapeutic response & increases
the relapse rate
âș Leishmania/HIV co-infection has so far been reported
from 33 countries worldwide, most commonly from
Brazil (in Americas) and India ( in Asia)
âș Introduction of HAART decreases the incidence of
leishmania infection in HIV positive patients
75. LEISHMANIASIS IN HIV INFECTION
âș Cutaneous involvement is seen in 2-12% of patients
with leishmania/HIV co-infection
âș Causes a variable spectrum of lesions â papular,
maculopapular & nodular
âș Leishmania amastigotes have been found in
apparently normal skin, infestating sweat ducts, &
co-existing with lesions of KS, HSV & HZV
âș Leishmania is also associated with changes
attributable to other dermatological processes like
dermatofibroma, psoriasis, Reiters disease, bacillary
angiomatosis, cryptococcosis & oral aphthae
76. LEISHMANIASIS IN HIV INFECTION
âș Can present as dermatomyositis like eruption
âą mucocutaneous & mucosal
leishmaniasis
âą post kala-azar leishmaniasis
âș Primary cutaneous lesions can visceralize in severely
immunodepressed patients
77. LEISHMANIASIS IN HIV INFECTION
DIAGNOSIS
âș Gold standard for diagnosis of leishmsniasis in HIV infected
individuals remains the isolation or identification of parasite
from appropriate tissue
âș Detection of leishmania amastigotes & antigens in
peripheral blood has sensitivity of 50% which increases to
70% after culture
âș New PCR techniques like detecting highly variable regions
of kinetoplast DNA & nested PCR have a sensitivity of
95.45% in peripheral blood & 100% in bone marrow
78. LEISHMANIASIS IN HIV INFECTION
TREATMENT
âș Duration of treatment has to be prolonged until 4 weeks
âș More likely to suffer from adverse events
âș Low rate of clinical & parasitological response â 60% with
antimonials or with amphoterecin B
âș 25-60% patients experience relapse during first year after
completing treatment
âș Combining antimonials with allopurinol/IFN-Îł useful in
refractory cases or in relapses
79. LEISHMANIASIS IN HIV INFECTION
SECONDARY PROPHYLAXIS
âș Antimonials 20 mg/kg once a month â some degree of
efficacy is seen
âș Pentamidine every 3-4 weeks
âș liposomal AMB every 2 weeks
âș Allopurinol/ itraconazole
Usually withdrawn when CD4+ cell count > 200/”l
80. âș My references are :-
âą Textbook of dermatology âRook
Fitzpatrick
âą J Postgrad Med 2003
âą J Am Acad Dermatol 1994, 1996
âą Clin Infect Dis. 1997, 2001, 2006
âą Drugs 1998; 56: 1009-1018
âą Int. J. Dermatol 1994, 1998, 2002
âą Trans R Soc Trop Med Hyg. 2006
âą Clin Exp Dermatol 2006